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Abstract
Olfactory ensheathing cell (OEC) transplantation is a promising strategy for treating spinal
cord injury (SCI), as has been demonstrated in experimental SCI models and naturally
occurring SCI in dogs. However, the presence of chondroitin sulphate proteoglycans within
the extracellular matrix of the glial scar can inhibit efficient axonal repair and limit the thera-
peutic potential of OECs. Here we have used lentiviral vectors to genetically modify canine
OECs to continuously deliver mammalian chondroitinase ABC at the lesion site in order to
degrade the inhibitory chondroitin sulphate proteoglycans in a rodent model of spinal cord
injury. We demonstrate that these chondroitinase producing canine OECs survived at 4
weeks following transplantation into the spinal cord lesion and effectively digested chondroi-
tin sulphate proteoglycans at the site of injury. There was evidence of sprouting within the
corticospinal tract rostral to the lesion and an increase in the number of corticospinal axons
caudal to the lesion, suggestive of axonal regeneration. Our results indicate that delivery of
the chondroitinase enzyme can be achieved with the genetically modified OECs to increase
axon growth following SCI. The combination of these two promising approaches is a poten-
tial strategy for promoting neural regeneration following SCI in veterinary practice and
human patients.
Introduction
Trauma to the spinal cord can lead to permanent loss of function. The injury initiates a cas-
cade of secondary biochemical events including inflammation, excitotoxicity, demyelin-
ation, axonal loss and cell death, causing irreparable sensory and motor dysfunction [1–3].
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As the pathophysiology following spinal cord injury (SCI) is complex, a combination of
approaches is likely to be required in order to combat the diverse factors impairing recovery
[4–6].
The glial scar is a major contributor to failed regeneration in the mammalian central ner-
vous system due to the inhibitory effect of chondroitin sulphate proteoglycans (CSPGs) on
regenerating axons [7]. Enzymatic digestion of the glycosaminoglycan side-chains on CSPGs
with the bacterial enzyme chondroitinase ABC (ChABC) leads to axonal regeneration and
plasticity [8–10]. In addition, ChABC disrupts the perineuronal nets found around intact syn-
apses leading to increased plasticity in surviving neurons [11, 12]. Together, these mechanisms
have resulted in functional improvement in experimental spinal cord injury (SCI) in rodents
[13–17] and in experimental spinal cord hemisection in cats [18, 19] following ChABC
delivery.
The ChABC enzyme rapidly degrades at body temperature [20] and this has limited its
translational potential. To circumvent this, the ChABC protein has been thermo stabilised
using a sugar trehalose to prolong its activity for up to 4 weeks [21]. The bacterial ChABC gene
has also been modified to allow effective secretion from mammalian cells [22] and delivery of
this gene into the injured spinal cord leads to large scale digestion of CSPGs in vivo [23, 24].
Due to its pleiotropic actions which do not overlap with other experimental therapies, ChABC
is thought to work well in combination with other therapies, such as cell transplantation, to
encourage recovery from SCI [6].
Cell transplants, such as olfactory ensheathing cells (OECs), can be used as a substrate to
support nerve regeneration, addressing the lack of trophic provision neurons encounter fol-
lowing central nervous system injury [25]. Other beneficial effects of OECs include their ability
to modulate the immune response [23], interact with reactive astrocytes [26], promote remye-
lination and form cell bridges to facilitate neural regeneration [27]. OEC transplantation in
spinal cord lesions has been shown to improve locomotor function in experimental models of
SCI [28, 29], in dogs with naturally occurring injuries [30], and have progressed to clinical tri-
als in people [31–33].
Naturally occurring canine SCI represents a useful translational bridge between experimen-
tal rodent models of SCI and human clinical trials [34–36]. Canine OECs can be safely col-
lected from the nasal mucosa, cultured in vitro and autologously transplanted into spinal cord
lesions [30]. We have previously demonstrated that these canine OECs can be genetically mod-
ified to produce the mammalian-modified form of ChABC in vitro [37]. We further show here
that canine OECs can act as a vehicle for delivering active ChABC to the site of SCI in rats.
This novel combination therapy is effective at digesting CSPGs in vivo, increasing axonal
regeneration and sprouting.
Materials and methods
All procedures were performed in accordance with the United Kingdom Animals (Scientific
Procedures) Act 1986 and were approved by the University of Bristol Animal Welfare and Eth-
ical Review Body.
For procedures, animals were anaesthetised with intraperitoneal injections of 60mg/kg
ketamine and 0.25mg/kg medetomidine. Post-operative analgesia was provided in the form of
subcutaneous injections of 0.01mg/kg of buprenorphine.
For euthanasia, all animals were deeply anaesthetised using sodium pentobarbital (200mg/
kg intraperitoneal) and transcardially perfused with 0.9% saline followed by 4% paraformalde-
hyde in 0.1M phosphate buffer.
Canine olfactory ensheathing cells transplantation after spinal cord injury
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Cell culture
Olfactory mucosa cells were collected from a fresh canine cadaver within 10 minutes of eutha-
nasia. This pet dog presented to our veterinary clinic and was euthanized for medical reasons
unrelated to this research. Owner consent was obtained and ethical permission was granted by
our local ethical committee (Veterinary Investigation Number: 13/033). Cells were collected
via endoscopic nasal mucosa biopsy and prepared according to previously published methods
[38]. Cells were maintained in culture on poly-l-lysine coated flasks containing DMEM, 10%
FBS, 2μM forskolin, 20 ng/mL neuregulin-1 and 1% penicillin and streptomycin. All cells in
culture were fed by replacing half of the media with fresh media every 3–4 days.
Lentiviral production and transduction
The lentiviral transfer vector used to deliver the mammalian-compatible Proteus vulgaris
ChABC gene [22] and the GFP gene to canine OECs was identical to the pRRL-CMV-ChABC-
SFFV-GFP vector previously reported [37]. The control transfer vector pRRL-CMV-GFP
expressed solely GFP. One week prior to cell transplantation canine OECs were passaged into
24 well plates (1.9 cm2 diameter wells) at 2 x 104 cells/cm2. Cells were transduced at 1 day in
vitro with the either the lentiviral vector pRRL-CMV-ChABC-SFFV-GFP or pRRL-CMV-GFP
at a multiplicity of infection (MOI) of 10.
Morgan-Elson assay
A Morgan-Elson assay [39] was performed on 6 samples of cell culture media from each group
immediately prior to cell transplantation. This assay detects the disaccharide breakdown prod-
ucts of CSPG digestion following exposure to ChABC. N-acetylation of the disaccharide degra-
dation products results in a colour change. This assay has been adapted to allow a quantitative
measure of active ChABC enzyme. Concentrations are expressed in U/mL [22] and performed
as described in [37].
Immunocytochemistry
Cells were fixed with 4% paraformaldehyde for 10 min and immunolabelled using mouse anti-
nerve growth factor receptor (p75NGFR) (MAB5264, Millipore, Germany; 1:200), rabbit anti-
fibronectin (A0245, Dako, Denmark; 1:400) and chicken anti-GFP (Abcam; 1:2000). Second-
ary antibodies were anti-mouse 546 (Abcam, UK; 1:500), anti-rabbit 660 (Abcam, UK; 1:400)
and anti-chicken 488 (Abcam, UK; 1:500). Coverslips were mounted using hard-set mounting
medium containing DAPI (Vectashield). The transduction efficiency was calculated using
ImageJ by counting the number of p75NGFR positive cells (OEC marker) that were also GFP
positive. Cell purity was calculated by counting the number of p75NGFR positive cells and the
number of fibronectin positive cells (olfactory nerve fibroblasts) and expressing this count as a
percentage of the total number of DAPI positive cells.
Spinal cord injury and cell transplantation
All procedures were performed in accordance with the United Kingdom Animals (Scientific
Procedures) Act 1986 and were reviewed by the University of Bristol Ethical Review Group.
Experiments were performed on adult 250g male athymic nude rats (ENVIGO, hsd:RH-
Foxn1rnu), housed with an enriched environment under a standard 12 h light/dark cycle, in a
laminar flow unit, with ad libitum access to food and water. Nude rats were used to reduce the
risk of rejection following xenotransplantation. All animals were anaesthetised with intraperi-
toneal injections of 60mg/kg ketamine and 0.25mg/kg medetomidine. The skin over the dorsal
Canine olfactory ensheathing cells transplantation after spinal cord injury
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cervical region was clipped and aseptically prepared. Following a dorsal laminectomy at the 4th
cervical vertebrae, the dura was cut to expose the spinal cord in this region. A dorsal column
crush to damage the corticospinal (CST) tract was performed as previously described [13].
Post-operative analgesia was provided in the form of subcutaneous injections of 0.01mg/kg of
buprenorphine every 6 hours.
Cell cultures were prepared for transplantation on the day of surgery and injected into the
spinal cord within 1 hour of detachment from flasks. Cells were trypsinised, washed twice in
calcium and magnesium free Hank’s balanced salt solution and resuspended in the same solu-
tion at a cell concentration of 4 x104 cells per μL. A total of 8 x104 cells were injected into the
spinal cord with two injections of 4 x104 cells each. Injections were given immediately rostral
and caudal to the lesion, at a depth of 1mm, in the midline, at a rate of 0.2 μL per minute using
a microinjector (UMP Pump II, World Precision Instruments). Twelve animals were used,
with 6 animals per group. The 2 groups consisted of those transplanted with canine OECs
transduced with pRRL-CMV-GFP (OECs group) and those transplanted with canine OECs
transduced with pRRL-CMV-ChABC-SFFV-GFP (OECs+ChABC group). The number of ani-
mals used for quantitative analyses are detailed in the respective sections.
Corticospinal axon labelling
Two weeks prior to termination of the experiment, descending CST axons were labelled by
injecting 1μL of 10% biotinylated dextran amine (BDA) (MW 10 000, Molecular Probes) bilat-
erally into the sensorimotor cortex at 6 sites per hemisphere. All animals were anaesthetized as
for the SCI / cell transplantation procedure and stereotaxic injections were made at a depth of
2 mm dorsoventrally into the sensorimotor cortex region using the following injection coordi-
nates as determined from a microstimulation mapping study [40]: in reference to bregma; AP,
anterior–posterior; L, lateral) AP −1.5 mm, L 2.5 mm; AP −0.5 mm, L 3.5 mm; AP +0.5 mm,
L 3.5 mm; AP +1.0 mm, L 1.5 mm; AP +1.5 mm, L 2.5 mm; AP +2.0 mm, L 3.5 mm.
Histopathology
Four weeks after SCI and cell transplantation, all animals were deeply anaesthetised using
sodium pentobarbital (200mg/kg intraperitoneal) and transcardially perfused with 0.9% saline
followed by 4% paraformaldehyde in 0.1M phosphate buffer. Tissue was collected immedi-
ately, mounted in 10% gelatin blocks and fixed overnight in 4% paraformaldehyde at 4˚C, fol-
lowed by immersion in 30% sucrose in phosphate buffer for 2 days at 4˚C. Gelatin mounted
tissue was frozen in optimized cutting compound (OCT, TissueTek) before sectioning. For
ChABC activity, lesion size and cell survival determination and quantification of labelled
axons, the spinal cord containing the lesion site was sectioned dorsally (40μm) with a cryotome
and kept free-floating in phosphate buffered saline at 4˚C for immunohistochemistry. 30μm
transverse sections of the spinal cord at 2cm rostral and 2cm caudal to the injury were also
obtained for determination of BDA labelled axons and PKCγ detection.
All primary antibodies were incubated overnight at 4˚C. To verify complete disruption of
the CST, transverse sections from each animal were immunostained with rabbit polyclonal
anti-PKCγ (Santa Cruz, 1:1000), to visualise the CST, and CST appearance was compared ros-
tral and caudal to the injury. To demonstrate in vivo ChABC activity, dorsal sections at the site
of injury were immunostained with either mouse monoclonal anti-chondroitin-4-sulphate
(MP Biomedicals, 1:5000), to reveal digested proteoglycan stub regions, or mouse monoclonal
anti-neurocan (Developmental Studies Hybridoma Bank, concentrated version 1:50) to label
intact CSPG. Complementary secondary antibodies were biotinylated goat anti-mouse or anti-
rabbit (Vector Labs, 1:500). Sections were then processed using the avidin-biotin amplification
Canine olfactory ensheathing cells transplantation after spinal cord injury
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method with conjugated peroxidase (Vector Labs, Vectastain ABC Elite Kit) and visualized
with 3–3’-diaminobenzidine (DAB) and NiCl2 (DAB peroxidase substrate kit, Vector Labs).
To identify transplanted cells, sections were immunostained using the following primary anti-
bodies: mouse anti-nerve growth factor receptor (p75NGFR) (MAB5264, Millipore, Germany;
1:200), rabbit polyclonal anti-glial fibrillary acidic protein (anti-GFAP) to label astrocytes
(Dako, 1:1000) and chicken anti-GFP (Abcam, 1:2000). Complementary secondary antibodies
applied for 2 hours at room temperature included: donkey anti-mouse Alexa Fluor 546 (Invi-
trogen, 1:500), donkey anti-rabbit Alexa Fluor 660 (1:500, Invitrogen) and donkey anti-
chicken Alex Fluor 488 (Invitrogen, 1:500). Fluorescently labeling of BDA axons was per-
formed using an Avidin-Neutravidin Texas Red secondary (Thermofisher, 1:500) overnight at
4˚C.
For determination of lesion size, dorsal sections were mounted and dried onto slides. Sec-
tions were stained for 1 min in Thionin, rinsed with distilled water, then dipped in 0.5% Eosin
for 10 s, followed by rinsing with distilled water. Sections were dehydrated, mounted in xylene
and the lesion size was quantified using ImageJ software (NIH, Bethesda).
Quantification of corticospinal axons
Three serial dorsal sections incorporating the CST, from 8 animals (4 per group), were used
for quantification of axonal sprouting, axonal regeneration and axonal dieback. Methods for
sprouting and dieback were taken from Garcia-Alias, Barkhuysen (15) and Wang, Ichiyama
(16). For axonal sprouting, each labelled CST axon sending a branch medially or laterally was
counted. For axonal dieback, the number of labelled axons within 2mm of the rostral aspect of
the lesion were counted. For axonal regeneration, the number of axons at 1mm, 2mm and
3mm caudal to the lesion were counted. Each axon count was normalized to the total number
of labelled CST axons for each animal. This was determined by calculating the mean number
of labelled axons in the 3 rostral transverse spinal cord sections. Sprouting axons were counted
manually and all other counts were counted using a semi-automated method [41].
Statistical analysis
Data are shown as mean +/- SEM. Axon count data were analysed by the Student’s t test where
there were two groups and mixed ANOVA and Bonferroni post hoc analysis where each ani-
mal was split into 3 anatomical regions.
Results
Preparation of the canine olfactory ensheathing cell transplant
The purity of olfactory ensheathing cell cultures generated from the canine olfactory mucosa
can vary from culture to culture, depending on the biopsy. We characterised the preparation
used in this study by assessing the proportion of p75NGFR positive cells and showed that the
canine olfactory mucosa culture consisted of 100% p75NGFR positive cells, with an elongated
bipolar morphology, consistent with OEC phenotype (Fig 1A). These cells also expressed low
levels of fibronectin, a property of OECs in culture as previously described [42]. No visible
contaminating fibroblasts that are identified by robust fibronectin labelling and a round, flat
morphology, as exemplified by a different culture containing fibroblasts in Fig 1E, were
detected (Fig 1B). Using the transduction protocol described, 95% of cells were transduced at a
multiplicity of infection of 10 (Fig 1C). Immediately prior to transplantation, cells transduced
with the pRRL-CMV-ChABC-SFFV-GFP vector were secreting 0.1 U/mL of active ChABC in
vitro and were easily identifiable by robust GFP expression. As expected, ChABC production
Canine olfactory ensheathing cells transplantation after spinal cord injury
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by cells transduced with the pRRL-CMV-GFP vector were negligible (0.003±0.00U/mL) (Fig
1F). Enzyme production was not recorded at zero due to a small degree of error in the Mor-
gan-Elson assay, and is highly unlikely to be due to the presence of ChABC given the make up
of the vector construct.
Canine olfactory ensheathing cells survive and migrate following
transplantation into the injured spinal cord
Following culture and characterisation of OECs, 80,000 of either GFP- or ChABC-producing
OECs were transplanted in a total volume of 2μL rostral and caudal to the spinal cord lesion.
Transplanted OECs expressing GFP were identified four weeks following transplantation into
nude rat spinal cords (Fig 2). Transplanted cells were found intermingled with reactive astro-
cytes at the site of injury (Fig 2A). These cells continued to express p75NGFR in vivo and main-
tained their bipolar morphology seen in culture (Fig 2B). The mean percentage of cells that
survived to 4 weeks post-transplantation was 6.5% (+/- SEM, 2.5%), with no significant differ-
ences in survival between the two groups (10.4±4.0 for GFP cells vs 7.0 ± 0.9 for ChABC-pro-
ducing cells). ChABC-producing OECs were found migrating up to 5mm caudal to the site
of transplantation within white matter tracts (Fig 2C), with the majority of cells remaining at
the site of spinal cord lesion. However, further assessment revealed that the number of cells
migrating away from the injection site did not differ significantly between the OEC-GFP and
the OEC-ChABC groups, possibly due to the small sample size.
Fig 1. Immunohistochemical and biochemical analyses of canine mucosa OECs prior to transplantation. The cells have been genetically modified
using the lentiviral vector pRRL-CMV-ChABC-SFFV-GFP to produce ChABC and GFP. All cells strongly expressed p75NGFR (A) and weakly expressed
fibronectin (B). 95% of OECs were transduced by the lentiviral vectors, as identified by the expression of GFP (C) and p75NGFR (D). (E) Example of
positive staining of fibronectin in contaminating fibroblasts (indicated by white arrows) in a different culture preparation. (F) Transduced cells secreted
robust quantities of active ChABC in culture, as detected by the Morgan-Elson enzyme assay. Scale bar 50μm.
https://doi.org/10.1371/journal.pone.0188967.g001
Canine olfactory ensheathing cells transplantation after spinal cord injury
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Olfactory ensheathing cells secreting chondroitinase ABC digest
chondroitin sulphate proteoglycans in vivo
The spinal cord sections were examined for evidence of CSPG digestion by transplanted OECs
secreting ChABC, compared to GFP-expressing OECs (Fig 3). The antibody anti-C4S detects
digested glycosaminoglycan stubs which are only present following ChABC-mediated diges-
tion of CSPG. Spinal cord sections including the lesion site showed no labelling in all animals
that received GFP-expressing OECs (Fig 3A and 3B). Furthermore, widespread labelling for
intact CSPG was present, as detected by neurocan immunolabelling (Fig 3C and 3D). In con-
trast, spinal cord sections from animals transplanted with ChABC-producing OECs demon-
strated C4S labelling up to 3mm surrounding the lesion, providing evidence of functional
ChABC activity (Fig 3E). High magnification at the border of CSPG digestion showed the
clear distinction in the presence and absence of C4S labelling (Fig 3F). Intact CSPG labelled
with the anti-neurocan antibody also demonstrated a clear halo of digested CSPG surrounding
the lesion (Fig 3G and 3H).
Fig 2. Transplanted canine mucosa OECs can be found at the lesion site at 4 weeks following transplantation. Genetically modified OECs can be
identified due to the expression of GFP (green). These bipolar spindle shaped cells also express the nerve growth factor receptor p75NGFR (red, white
arrow). Cells intermingle with reactive astrocytes expressing GFAP (blue) around the lesion penumbra (A, B). Elongated OECs were seen migrating up to
5mm caudal to the lesion within the dorsal column white matter tracts (C). * = lesion centre. Scale bar A, 100μm. B, 25μm.
https://doi.org/10.1371/journal.pone.0188967.g002
Canine olfactory ensheathing cells transplantation after spinal cord injury
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Spinal cord sections were examined for the presence of fluorescently labelled OECs at the
lesion site and the presence or absence of C4S labelling surrounding cell transplants (Fig 4).
C4S labelling at the site of transplantation was absent in all animals that received OECs pro-
ducing GFP (Fig 4A–4C). All animals transplanted with ChABC producing OECs showed C4S
labelling surrounding transplanted cells (Fig 4D–4F). The most intense C4S labelling was
localised to the site of SCI, likely due to the higher quantity of CSPGs present within the glial
scar. A lower intensity of C4S labelling was also present surrounding these intensely labelled
regions, possibly due to digestion of CSPGs in perineuronal nets. High magnification imaging
of this C4S intense region showed transplanted cells, identified by robust GFP expression and
a bipolar spindle like morphology (Fig 4G–4I).
Chondroitinase ABC producing olfactory ensheathing cells increase
axonal sprouting following corticospinal tract injury
Corticospinal tract (CST) axons were labelled by injecting 10,000 MW biotinylated dextran
amine (BDA) bilaterally into the sensorimotor cortex. All 12 animals had complete destruction
of the CST at the C4 spinal cord segment following a dorsal column crush injury, as shown by
the absence of PKCγ labelling caudal to the site of injury (arrowhead Fig 5B, S1 Fig). The CST
Fig 3. CSPG digestion by canine mucosa OECs producing ChABC in vivo. OECs expressing GFP did
not digest CSPGs as shown by the lack of C4S immunolabelling in (A) and the presence of robust neurocan
immunolabelling in (C). (B) and (D) are high magnification images of the regions highlighted in (A) and (C).
OECs producing ChABC digested CSPGs revealing C4S epitopes around the site of injury (E). High
magnification image of the highlighted region in E demonstrates the transition between digested (top right of
F) and intact (bottom left of F) CSPG (F). CSPG digestion removes neurocan from the site of injury and in a
3mm halo around the lesion (G). High magnification image of the highlighted region in G demonstrates the
absence of neurocan immunolabelling (right of box H) around the lesion. Asterisk * on panel A, C, E and G
represents the experimental lesion. Scale bar A, C, E, G 1mm. Scale bar B, D, F, H 200μm.
https://doi.org/10.1371/journal.pone.0188967.g003
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Fig 4. Canine mucosa OECs producing ChABC digest CSPGs at the site of spinal cord lesion. OECs lacking ChABC do not cause any visible
CSPG digestion as shown by the lack of C4S immunoreactivity surrounding OECs expressing GFP (A-C). There is widespread C4S immunolabelling in
animals transplanted with ChABC-producing OECs, particularly around the site of the spinal cord lesion (D-F). High magnification image of box in (F)
shows easily identifiable GFP labelled transplanted OECs associated with regions of intense CSPG digestion (G-I). Scale bar A, B, 100μm C, 25μm.
https://doi.org/10.1371/journal.pone.0188967.g004
Canine olfactory ensheathing cells transplantation after spinal cord injury
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can be seen rostral to the lesion in the ventral aspect of the dorsal funiculus (arrowhead Fig
5A). Histological examination of the H&E stained sections showed that the lesion size did not
significantly differ between the two groups (Fig 5C–5F).
The number of branching axons arising rostral to the damaged CST was compared between
the two transplant groups. The count was normalised for each animal based on the number of
BDA labelled CST axons identified in a rostral cervical transverse section. Branching axons
were seen in both groups but there was a significant increase in the number of branching
axons in animals transplanted with ChABC producing OECs (Fig 6C). Occasionally these
branching axons crossed the grey to white matter boundary (Fig 6A and 6B).
The number of intact axons identified caudal to the lesion was compared between groups
(Fig 6D, 6E and 6F). Within 1mm caudal to the lesion there was no difference in the number
of axons between spinal cord lesions containing control OECs and OECs producing ChABC.
At 1-2mm caudal to the lesion there was a higher number of axons seen in animals trans-
planted with OECs producing ChABC however this did not reach significance. At 2-3mm cau-
dal to the lesion there were significantly more CST axons seen in animals transplanted with
OECs producing ChABC compared to those receiving OEC-GFP transplants (p = 0.005,
mixed ANOVA). These axons seen caudal to the lesion could either have sprouted from the
unlesioned lateral CST or represent regenerating axons. In animals transplanted with OECs
producing ChABC, tortuous axons were seen traversing the injury, closely associated with the
lesion cavity, and extending into the normal portion of spinal cord caudally. In contrast, this
was not seen in animals transplanted with GFP expressing OECs, where axons ended at the
lesion in dystrophic endbulbs (S2 Fig).
As the cell transplant was given at the time of spinal cord section (i.e. mimicking the acute
phase of SCI), it may have provided some neuroprotection to damaged neurons. To assess this
Fig 5. Demonstration of complete CST injury. Transverse section of the cervical spinal cord rostral to the dorsal column
crush injury immunolabelled for PKCγ to show intact CST axons (A). The arrow indicates the location of the CST in the dorsal
columns. Transverse section taken caudal to the site of injury showing the absence of corticospinal axons in the dorsal
columns (B). Spinal cord lesion can be visualised in thionin-eosin stained spinal cords of animals receiving OEC-GFP (C) and
OEC-ChABC (D). No significant differences in the lesion size were detected between the two groups (n = 3). Scale bar 500μm.
https://doi.org/10.1371/journal.pone.0188967.g005
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Fig 6. ChABC produced by genetically modified OECs leads to increased sprouting of CST axons rostral to the lesion and
increased number of CST axons caudal to the lesion. Sprouting CST axons were observed rostral to the lesion, as indicated by
arrowheads (A, B). The yellow dashed line in A and B indicates the grey to white matter boundary and white matter is to the left of the
images. Significantly more sprouting CST axons were seen in animals transplanted with OECs producing ChABC (C; P = 0.0028, Student’s
t-test, n = 4). BDA-labelled axons travelling from rostral (left) to caudal (right) in the dorsal CST are shown in white (D, E). Axons were seen
extending over 3mm caudal to the lesion in all animals but significantly more axons were seen in animals transplanted with OECs producing
ChABC (F, n = 4). The degree of axonal dieback, assessed by counting the number of CST axons immediately rostral to the lesion, was not
different between groups (G, H, I, n = 4). High magnification images G and H are taken from images D and E with the dotted line to the right
of the images indicating the lesion. ** = p<0.01. Scale bar A, B = 50μm. D, E = 1mm. G, H = 0.25mm.
https://doi.org/10.1371/journal.pone.0188967.g006
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we compared the degree of axonal dieback between the two groups (Fig 6G, 6H and 6I). No
significant difference was observed between the two groups and the axon counts were similar
between groups. BDA-labelled CST axons could be seen abutting the cystic cavity in animals
transplanted with control OECs and OECs producing ChABC.
Discussion
In this proof of concept study, we have shown that OECs dissected from the canine mucosa
and cultured in vitro can be genetically modified to secrete functional mammalian-modified
ChABC in vivo at the site of SCI following transplantation. This led to digestion of CSPGs in
and around the site of injury and was associated with an increase in axonal sprouting and puta-
tive axonal regeneration in the CST.
The OEC cultures used for these experiments were collected from the olfactory mucosa of a
companion dog immediately following euthanasia using a minimally invasive technique. The
purity of OEC cultures can vary from culture to culture if no purification steps are employed,
and this has been documented in samples of the olfactory mucosa from humans [43, 44]. For
clinical translation, characterisation of cell purity and identification of any contaminating cells
prior to transplant will be crucial in light of a case report of a spinal cord mass that developed
after olfactory mucosal cell transplantation in a patient with a spinal cord injury [45]. The
mass comprised cells of the respiratory epithelium and submucosal glands, however it is note-
worthy that this transplant was neither characterised nor cultured prior to transplantation. In
other studies reporting long-term follow-up of humans transplanted with ‘cultured OECs’, no
adverse effect was observed [46–47]. Protocols are now available for culture of human OECs
in view of transplantation [48]. In our transplantation experiments, we did not find any con-
taminating fibroblasts, and all cells were p75NGFR positive, a marker whose utility for OEC
purification has been recently highlighted [49]. Previous cultures using this technique have
documented cell purities of around 85% [37], and the high percentage of p75NGFR positive
cells, presumed to be olfactory ensheathing cells, may be an important contributing factor to
facilitating axonal regeneration. As the p75NGFR marker also detects Schwann cells, it is possi-
ble that our culture contains Schwann cells but this is unlikely given that OECs are the pre-
dominant p75NGFR positive cell type in the olfactory mucosa and we and others practice
careful dissection and removal of respiratory mucosa and blood vessels (the main source
of Schwann cells) before the start of the culture. Nonetheless, in the absence of a specific
marker for OECs we cannot discount the possibility that contaminants are present in OEC
transplants.
We chose to explore this ex vivo gene delivery method as it can provide a further degree of
safety compared with in vivo gene delivery [50]. OECs, a fully differentiated cell type, were
transduced in vitro using a self-inactivating lentiviral vector, prior to transplantation, with no
exposure of viral vector to host tissue. Meta-analysis of 49 OEC transplantation studies in rat
models of SCI by Watzlawick et al. [51] indicated that the stable effect sizes range between
10,000–100,000 cells in a volume of up to 2.9μL, with high dose cellular transplants in high
injection volumes causing neurotoxicity. Based on these and previous studies [30], we trans-
planted 80,000 cells in a total volume of 2μL rostral and caudal to the spinal cord lesion. Trans-
plantation of the genetically modified OECs provided a sustainable source of ChABC to
effectively digest the inhibitory CSPGs at the lesion site. Other groups have investigated the
safety of long-term delivery of ChABC to the CNS [23, 52–54] and found no evidence of neu-
ropathic pain or autonomic dysreflexia, both theoretical complications of inducing plasticity
in host axons [55–57]. A further desirable safety feature would be to regulate expression of
ChABC, for example by using a tetracycline regulatable system [58, 59] whereby ChABC
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production could be controlled by systemic tetracycline analogues. This could allow the gene
therapy to be switched off at a precise clinical end point or if adverse events are identified, fur-
ther improving the safety of the therapy. Another advantage of ex vivo gene delivery is that it
allows tracking of transplanted cells, in experimental injury models, by incorporating a fluo-
rescent reporter gene [60].
Intense anti-C4S labelling was found at the site of injury in animals transplanted with
OECs producing ChABC. The C4S antibody recognises a glycosaminoglycan stub that is only
revealed following digestion of CSPGs with ChABC. The intense labelling is likely due to
digestion following the up-regulation of CSPGs that occurs at the glial scar [61–63]. The obser-
vation of strong anti-C4S labelling surrounding this CSPG rich region is also likely due to
digestion of CSPGs associated with the perineuronal nets of normal neuronal synapses [64].
These two distinct sites containing intense staining for digested CSPGs are consistent with the
two main mechanisms of action of ChABC following SCI, namely removal of CSPGs from the
glial scar promoting axonal regeneration and the breakdown of perineuronal nets promoting
plasticity of surviving neurons [8, 65].
More axons were observed caudal to the injury site in animals transplanted with OECs pro-
ducing ChABC compared to controls and this difference was most evident at 2 to 3mm caudal
to the lesion. This suggests that the combination of OECs with ChABC enhanced the growth-
promoting properties of the OECs, enabling longer-range regeneration of injured or spared
axons. Some of these axons could be seen traversing the injury site and extending caudally;
these may be regenerating axons or plasticity elicited from spared fibres. It is also possible that
axons may have bypassed the lesion and reconnected with the caudal CST, a recognised find-
ing in spinal cord injured animals treated with ChABC [16, 66].
We observed a mean survival rate of 6% at 4 weeks post-transplantation. Poor cell survival
may be due to a number of factors, such as the timing of the transplantation, immune rejection
of the grafted cells particularly in a xenotransplant paradigm, hostile environment of the spinal
cord lesion or shock to the cells from culture to transplant [67]. Watzlawick et al. [51] in a
meta-analysis study suggested that transplantation in the hyperacute phase (5–30 min) was
associated with greater efficacy than transplantation in the subacute or chronic phases. Poor
cell survival is possibly due to the xenotransplantation of canine cells into the rodent species.
Although athymic rats that are T-cell deficient were used, these animals have normal B-cell
function and increased Natural Killer (NK) and macrophage cell populations. There is some
evidence that other components of the immune system can contribute to xenogeneic rejection,
for example NK cells play a more prominent role in xenograft rejection [68–69]. Khankan
et al. [70] showed that 14±8% OECs survive at the spinal cord lesion at 8 weeks post-transplan-
tation in immunosuppressed rats (cyclosporine A) receiving an allograft. Therefore, the sur-
vival rate of our transplanted cells is not surprising. Nonetheless, it will be necessary to test this
approach in a chronic injury model. We observed ChABC-producing OECs migrating up to
5mm from the site of transplantation, however upon further analysis there were no significant
differences in the migration rate between the two groups, possibly due to small sample size
and therefore further investigation is warranted. OEC migration is a common observation in
SCI studies [71–74] and the degree of migration is thought to have an influence on functional
recovery [75, 76]. OECs are thought to migrate ahead of regenerating axons and encourage
axon growth by secreting neurotrophic factors [77]. Recently it has been demonstrated that
CSPGs can impair OEC migration, and that addition of ChABC increased OEC migration
over CSPG substrates in an in vitro migration assay [78].
In previous spinal cord OEC transplantation studies in companion dogs, some cases
‘responded’ to the therapy whereas others were ‘non-responders’ and this has highlighted
the need to further improve the OEC transplantation therapy [30]. To achieve this, we have
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undertaken a ‘proof-of-concept’ study to test canine OECs genetically modified to secrete
ChABC in the context of a laboratory using homogeneous animals with similar injuries. This
can quickly detect the efficacy of the proposed treatment before embarking in a more com-
plex clinical trial in companion dogs (usually requiring at least 3 years). We used a xeno-
transplant model (canine cells into rodents), and athymic rats to reduce the risk of cell
transplant rejection. Transplanted cells survived at least 4 weeks. Cell survival times are
likely to be shorter in immunocompetent animals but studies utilising autologous transplan-
tation, in dogs and people, have indicated that transplant rejection is less likely to be an issue
in clinical cases [30, 32]. Having now gained knowledge on the potential of engineered
canine ChABC OECs, the next logical step would be to determine the longer term survival of
these cells and functional recovery in a chronic injury model. This could lead to further test-
ing in companion dogs used as a translational model, as recently highlighted by the CAN-
SORT-SCI group [36].
Conclusions
The current study shows that canine OECs, genetically modified to produce ChABC, are capa-
ble of digesting CSPGs following transplantation into the injured spinal cord and that this
CSPG digestion is associated with significantly more CST axons caudal to the injury, possibly
due to increased plasticity or new growth of axons. This provides an important proof-of-con-
cept and positions OECs expressing ChABC as a viable method to deliver ChABC inconjunc-
tion with the well-known added benefits of OEC transplantation. An efficacy question remains
but we are now well positioned to take this therapy further, for example by taking advantage of
companion dogs spontaneously affected by SCI. These are available to neuroscientists through
large veterinary hospitals to take part in randomised controlled clinical trials that could allow
detection of real-life functional benefits.
Supporting information
S1 Fig. Demonstration of complete CST injury. Transverse section of the cervical spinal cord
caudal to the dorsal column crush injury immunolabelled for PKCγ to show absence of corti-
cospinal axons in the dorsal columns in all animals, indicating complete CST injury.
(TIF)
S2 Fig. BDA labelled corticospinal axons at the site of injury. Tortuous axons (arrowhead
in A) can be seen traversing the site of injury and extending caudally (A). Axons are closely
associated with the lesion cavity and contain swellings suggestive of active growth (arrowhead
in B) (B). In control animals transplanted with OECs alone, axons end abruptly in retraction
bulbs suggestive of abortive regeneration (C).  = lesion centre. Caudal is to the right of the
images. Scale bar 100μm.
(TIF)
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